An Evolving Regulatory Landscape

Over the past few years, regulatory changes in the United States have initiated a shift toward non‑animal methodologies (NAMs) in drug development. First, this shift began with the FDA Modernization Act 2.0 released in 2022, which formally allowed non‑animal approaches, including computational models, to support IND submissions. This marked the first major milestone toward integrating NAMs into regulatory processes. In 2024, the FDA Modernization Act 3.0 expanded this framework by encouraging the use of AI‑driven models, organ‑on‑chip technologies, and next‑generation in‑vitro systems.

In parallel, the FDA’s Predictive Toxicology Roadmap has reinforced this direction by emphasizing the value of computational approaches in reducing animal use while improving the accuracy of safety predictions, and model‑informed drug development (MIDD) has emerged as a recognized regulatory priority by the FDA.

Together, these measures reflect a clear and growing regulatory support for in-silico toxicology as a credible and increasingly essential component of modern safety assessment.

What is In-Silico Toxicology?

In-silico toxicology is a scientific discipline that relies on computational models and machine‑learning algorithms to predict the potential toxicity of chemicals, including pharmaceuticals, cosmetics, and food ingredients. The predictive power of these models depends on a large toxicology database, which is frequently updated through the addition of curated data from public repositories, research publications, and regulatory agency reports. As these datasets grow and are continuously refined, the predictive capabilities of these in-silico models continue to gain precision, supporting coverage of a wider range of chemical structures and thereby delivering increasingly reliable estimations.

The core computational approaches include:

• (Q)SAR Models to identify structural patterns associated with toxicological outcomes.
• Expert Alerts to detect structural features linked to known toxicity mechanisms.
• Read‑Across to predict toxicity of novel compounds by comparison with structurally similar analogues.
• Integrated Multi‑Model Frameworks which combine statistical models, expert systems and, when required, curated datasets to deliver robust predictions.

These models support regulatory submissions and align with international guidelines like the ICH M7.

Toxicity Predictions and Smarter Drug Design

Computational models can evaluate a broad range of toxicity domains, including:

• Systemic Toxicity: Acute toxicity, carcinogenicity, reproductive and developmental toxicity, endocrine toxicity.
• Organ‑Specific Toxicity: Cardiotoxicity, hepatotoxicity, nephrotoxicity, neurotoxicity.
• Irritation & Sensitization: Skin and eye irritation/corrosion, skin sensitization.
• Genetic & Metabolic Toxicity: Genotoxicity, metabolic activation, CYP inhibition.
• Environmental Toxicity: Ecotoxicity.

Our in‑silico platform not only predicts potential toxicity risks but also identifies the structural features that drive those effects, enabling clients to refine the molecular design of their drug.

These feature contribution analyses identify toxicophores (specific structural features within the molecule that are known to be associated with toxicological effects) and quantify their impact on predicted outcomes. Expert alert data further contextualize these potential risks by referencing published studies, species, strains, metabolic conditions, and experimental outcomes.

This combination of mechanistic insight and data‑driven prediction supports a more efficient drug design and compound optimization.

An Important Strategic Value

It becomes increasingly clear that in-silico toxicology offers practical advantages in the drug development process, providing safety insights without the need for large laboratory programs. Building on this observation, our in-silico toxicology prediction services help sponsors identify potential toxicity issues before moving into in-vivo studies, thereby reducing the likelihood of costly setbacks and lowering the risk of attrition in GLP toxicology programs. This approach can also strengthen confidence during fundraising and partnership discussions. In day‑to‑day development, in-silico data make it easier to prioritize candidates with a better safety profile and help programs move forward more efficiently. Just as importantly, they support today’s ethical expectations from regulators by reducing reliance on animal testing while maintaining the level of scientific rigor required in drug development.

The 5 key considerations of in-silico toxicology are:

• Cost‑Effectiveness
• Efficiency
• Scientific Confidence
• Ethical Practices
• Alignment with Modern Standards

Conclusion

In-silico toxicology is now recognized as an integral part of the modern regulatory and scientific landscape. As part of the broader NAMs ecosystem, ITR provides in-silico toxicology solutions to accelerate development timelines and support regulatory submissions. When integrated with in-vitro and in-vivo data, these models contribute to a robust safety package that supports both innovation and regulatory compliance. Beyond its predictive capabilities, our in-silico platform helps teams identify risks earlier, focus resources more effectively, and reduce unnecessary animal testing. As regulatory expectations continue to evolve increasingly toward data‑driven and mechanism‑informed approaches, incorporating computational toxicology becomes an essential asset when building efficient, ethical, and scientifically grounded drug development programs.